


Preventing potential

drug misuse for better

patient and community































outcomes

In the US, mental health conditions and substance use disorders (SUDs) have been on the rise. 1,2 This is no coincidence, as one can affect the other—and both can lead to drug misuse.³ The 2022 Quest Diagnostics® Health Trends® report confirmed nearly half of patients misuse their medication.² Greater attention must be paid to preventing drug misuse at the earliest stages of risk—and clinical drug testing can help. Additionally, health centers need tools to support them in addressing the underlying causes of drug misuse, including mental health conditions.

1 in 10

prescriptions in the US in 2022 were for anxiety and depression medications4

17M

people have both a mental illness and an SUD⁵

55%

of health centers provided SUD services for ~286K patients in 2021⁶

~99%

of HRSA health centers provide mental health services⁷

We can help you protect your patients and your health center with comprehensive drug monitoring and medication adherence testing solutions.

Mitigate risk and keep patients and communities safe with **clinical drug monitoring**



Monitoring medication adherence through drug testing can support you and your clinicians while also protecting your patients and communities. Our state-of-the-art drug testing offering can complement your health center's prescription drug monitoring program to provide a fuller picture of patient status. It can also help you meet the expectations of medical boards and regulatory agencies while helping your clinicians maintain patient access to prescription therapies.





Comprehensive menu—prescription drugs used in the treatment of chronic pain, ADHD, anxiety, depression, and SUDs; other controlled medications and substances of abuse



Performance—high-sensitivity low cutoff levels designed to detect drugs at typical dosage levels; fast turnaround time and results confirmation



Reporting—optional medMATCH[™] results interpretation; "inconsistent" when results do not match prescriptions provided by clinician; quarterly practice-level data and analytics



Connectivity and service—exceptional service and efficiency that aligns with your workflow; connectivity with over 920 EMR systems



Expert support—toxicology experts who can answer questions on test selection and results interpretation at 1.877.40.RXTOX (1.877.407.9869)



The right price—in network for >90% of lives nationwide; preferred lab network status with major health plans

Drug testing is supported by the CDC

opioids for subacute or chronic pain, clinicians should consider the benefits and risks of toxicology testing to assess for prescribed medications as well as other prescribed and nonprescribed controlled substances.8

Centers for Disease
Control and Prevention



Let's address drug misuse together.

Contact your Quest Diagnostics sales representative for more information or visit QuestDrugMonitoring.com.

References

1. NIH. Drug overdose death rates. Last updated June 30, 2023. Accessed December 18, 2023. https://nida.nih.gov/research-topics/trends-statistics/overdose-death-rates 2. Quest Diagnostics®. Quest Diagnostics® Health Trends®: Drug misuse in America 2022—a decade lost to the drug crisis. 3. CDC. Vital statistics rapid release: provisional drug overdose death counts. Last reviewed June 14, 2023. Accessed December 18, 2023. https://www.cdc.gov/nchs/nvss/vsrr/dug-overdose-data.htm 4. GoodRx Health. Fills for mental health prescription drugs rose during COVID and remain high. February 21, 2023. Accessed December 18, 2023. https://www.goodrx.com/healthcare-access/research/fills-for-anxiety-and-depression-prescription-drugs-rose-during-covid-pandemic 5. Substance Abuse and Mental Health Services Administration. (2021). Key substance use and mental health indicators in the United States: Results from the 2020 National Survey on Drug Use and Health (HHS Publication No. PEP21-07-01-003, NSDUH Series H-56). Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. https://www.samhsa.gov/data/ 6. HRSA. Health center program: impact and growth. Last reviewed August 2022. Accessed December 18, 2023. https://bphc.hrsa.gov/about-health-centers/health-center-program-impact-growth 7. HRSA. Behavioral health and primary care integration. Last reviewed April 2023. Accessed December 18, 2023. https://bphc.hrsa.gov/technical-assistance/clinical-quality-improvement/behavioral-health-primary-care-integration 8. Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC Clinical Practice Guideline for Prescribing Opioids for Pain—United States, 2022. MMWR Recomm Rep 2022;7(No. RR-3):1-95. doi:10.15585/mmwr.rr7103a1

Image features a model and is used for illustrative purposes only.

QuestDiagnostics.com

Quest, Quest Diagnostics, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. ©2024 Quest Diagnostics Incorporated. All rights reserved. SB12826 4/2024